JPRN-UMIN000030948已完成2 期
Propagermanium monotherapy in patients with relapsed or refractory cancer. - PG monotherapy in cancer patients
Hyogo College of Medicine, Institute for Advanced Medical Sciences0 个研究点目标入组 30 人开始时间: 2022年3月31日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 100years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) active lesion of the other type of cancer, except of gastric and head/neck cancer 2) Immunotherapy
研究者
相似试验
招募中
4 期
Prasugrel Monotherapy Following PrImary Percutaneous Coronary Interventionfor ST-elevation Myocardial InfarctioST-Elevation Myocardial InfarctionJPRN-jRCTs052220145akazawa Gaku2,258
招募中
Unknown
Peramapnel First-line Monotherapy in Idiopathic Gneralized EpilepsyJPRN-jRCTs031230053Masuda Yosuke30
进行中（未招募）
不适用
Treatment with Ofatumumab for RElapsed/refractory Splenic B-cell marginal zone lymphoma (MORE)EUCTR2013-004916-23-ITOspedale San Raffaele
招募中
2 期
Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-BBzeta retroviral vector – A unicenter Phase I/II clinical trial [HD-CAR-1]2024-516832-82-00Universitaetsklinikum Heidelberg AöR63
招募中
4 期
PRasugrEl Monotherapy Following prImary percUtaneous Coronary Intervention for ST-elevation Myocardial InfarctionST-segment Elevation Myocardial Infarction (STEMI)NCT05709626Kindai University2,258